Galderma has secured FDA approval for Restylane Contour for temple hollowing—a structural correction indication that addresses age-related volume loss in the temporal region. Restylane Contour is a thicker-gel HA formulation designed for deeper placement and structural support, distinct from Restylane Refyne (dynamic expression lines) and Restylane Lyft (cheek/hand volume).
Temple hollowing is a high-visibility sign of aging and a common patient concern, yet most practices have relied on off-label use of thicker fillers or Sculptra (PLLA biostimulator) for this zone. A cleared indication removes prescriber liability and creates a labeled, reimbursable pathway—though most aesthetic work remains cash-pay. The temple is a premium anatomical zone with strong patient demand and limited competitive pressure from other fillers.